IM Cannabis Corp. reports developments tied to its medical cannabis platform serving patients in Israel and Germany. Company updates commonly address medical cannabis operations, regulatory and commercial positioning, operating and financial results, and the management of liquidity through note purchase agreements, convertible notes and common share purchase warrants.
Recurring IMCC news also includes Nasdaq listing-compliance notices, board and executive appointments, shareholder or governance matters, and disclosures related to material agreements and capital structure. The company’s announcements frame IM Cannabis as an international medical cannabis issuer with cross-border supply and compliance considerations in regulated cannabis markets.
IM Cannabis Corp. (IMCC) has entered a multi-year supply agreement with GTEC Holdings Ltd. to import premium high-THC medical cannabis flower into Israel, strengthening its product offerings in one of the largest medical cannabis markets globally. The imports will commence in Q2 2021, subject to regulatory approvals, allowing IMC to launch a new category of indoor cannabis products under its established brand. This strategic partnership enhances IMC's international supply network and positions it favorably in the growing demand for imported cannabis in Israel.
IM Cannabis Corp. (CSE:IMCC) announced its shares will commence trading on the NASDAQ Capital Market today, marking it as the first Israeli medical cannabis operator to do so. This listing aims to enhance access to investments and improve liquidity for shareholders. IMC operates in Israel and Germany, with plans to expand into Canada post-acquisition of Trichome Financial. In Q3 2020, IMC reported $11 million in revenue, achieving 67% year-over-year growth. The company aims for long-term shareholder value through growth strategies and prudent capital allocation.